Plasmalogen levels begin to decrease after age 50. Persons with dementia exhibit a more rapid decrease in plasmalogens – especially omega-3 plasmalogens. ProdromeNEURO™ is designed to elevate omega-3 plasmalogens.

Plasmalogens are a critical component of brain membranes. The synaptic release of neurotransmitters (the core requirement for all nerve function) is dependent upon sufficient plasmalogen levels. Low brain plasmalogen levels are strongly correlated with reduced cognition.

Dr. Goodenowe studied all-cause mortality in 1,262 elderly persons of whom 557 had subsequently died and 705 were still living. The 5-year probability of dying (by any cause) was discovered to be heavily dependent upon the person’s baseline blood plasmalogen levels. 5-year mortality in 85-year-olds with high plasmalogens was 20%, but was 70% in 85-year-olds with low plasmalogens. A 95-year-old with high plasmalogens had the same probability of living to age 100 as a 65-year-old with low plasmalogens had of living to age 70.

With no viable dietary sources available to replenish plasmalogen deficiencies, Dr. Goodenowe pioneered the development of targeted plasmalogen precursors, a groundbreaking invention designed to restore plasmalogen levels across all body cells.

These precursors, rigorously tested and validated through extensive preclinical and clinical research, are now accessible as innovative dietary supplements – ProdromeNEURO™ and ProdromeGLIA™. Additionally, Dr. Goodenowe's ProdromeSCAN™ offers a specialized blood test to accurately measure your plasmalogen levels, complementing your health regimen with precise, science-backed insights.